Monday, February 10, 2025

Spanish Analysis Exposes Critical Gaps in Flu Vaccine Cost-Effectiveness for Seniors

Similar articles

A recent study conducted in Spain has highlighted significant uncertainties in the cost-effectiveness analyses (CEA) of newly introduced influenza vaccines for the elderly population. Despite following established guidelines, these analyses may not fully capture the complexities of vaccine effectiveness and influenza burden among older adults.

Table of Contents

Subscribe Weekly Market Access News

* indicates required

Methodological Approach

Researchers undertook a systematic review of Spanish CEAs published since 2016, focusing on those assessing influenza vaccines for seniors. Utilizing the TRansparent Uncertainty ASsessmenT (TRUST) Tool, along with quality assessment checklists and WHO guidelines, the study meticulously examined structural, methodological, and parametric uncertainties inherent in these analyses.

Identified Sources of Uncertainty

The review included seven CEAs that adhered to relevant guidelines. However, critical uncertainties emerged, particularly concerning the selection and application of efficacy and effectiveness data. Many studies relied on single-season real-world data or meta-analyses that incorporated studies with a high risk of bias or significant heterogeneity, leading to potentially skewed interpretations. Additionally, the estimation of influenza burden often encompassed fewer than five seasons and frequently used generalized influenza-like illness data, which may not accurately reflect the true impact on the elderly population.

Key Inferences:

  • Reliance on limited seasonal data may underestimate the variability in influenza impact.
  • Biases in meta-analyses can distort the perceived effectiveness of vaccines.
  • Generalized influenza-like illness metrics might not capture specific vulnerabilities of older adults.

These findings suggest that while the CEAs are systematically conducted, the underlying data and methodologies may introduce significant uncertainties that could influence healthcare decision-making processes regarding influenza vaccination strategies for the elderly.

Healthcare policymakers should exercise caution when interpreting CEA results, ensuring that decisions are informed by robust and comprehensive data. Enhancing the quality and scope of data used in these analyses can lead to more accurate assessments of vaccine cost-effectiveness, ultimately improving health outcomes for older adults.

Future research should aim to incorporate multi-season data and refine effectiveness measures to better reflect the true burden of influenza among seniors. By addressing these uncertainties, Spain can optimize its vaccination programs, ensuring they deliver maximum value and protection to its aging population.

Source

You can follow our news on our Telegram, LinkedIn and Youtube accounts.


This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article